Merck & Co.
AWARDS
NEWS
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
Seven pharma executives will enter the Congressional crucible next week as they face questions and concerns over the rising costs of prescription drugs.
Shares of Immune Design are skyrocketing in premarket trading today after Merck announced it will acquire the Seattle-based oncology company for $300 million in cash. Immune Design stock has shot up more than 310 percent to $5.83 in early trading.
Keytruda failed to show a statistical significance in overall survival and progression free survival in the Phase III trial.
Merck’s Keytruda paired with Pfizer’s Inlyta fares better than standard-of-care treatment in patients of advanced renal cell carcinoma.
The pharma giant announced plans to expand its immuno-oncology program with three new Phase III trials following promising data from a combination of Keytruda and Lynparza and other agents.
JOBS
IN THE PRESS